// App-Quantinova.ai

OC4.5 : Durability of response and gender-based analysis from the LINC3 trial of osilodrostat in the treatment in cushing’s disease

Researchers

Presenter

  • Rosario Pivonello

Principal Investigators

  • Maria Fleseriu

  • John Newell-Price

  • Bertagna Xavier

  • Findling James

  • Shimatsu Akira

  • Gu Feng

  • Auchus Richard

  • Leelawattana Rattana

  • Eun Jig Lee

  • Jung Hee Kim

  • Lacroix Andre

  • Beverly Biller

Medical Centers

  • Dipartimento di Medicina Clinica e Chirurgia, Universit Federico II di Napoli, Naples, Italy

  • Northwest Pituitary Center, Department of Medicine and Neurological Surgery, Oregon Health & Science University, Portland, OR, USA

  • The Medical School, University of Sheffield, Beech Hill Road, Sheffield, United Kingdom

  • Department of Endocrinology, Centre de Référence des Maladies Rares de la Surrénale, Hôpital Cochin, Faculté de Médecine Paris Descartes, Université Paris V, Paris, France

  • Division of Endocrinology, Metabolism, and Clinical Nutrition, Medical College of Wisconsin, Milwaukee, WI

  • Clinical Research Institute, National Hospital Organization Kyoto Medical Center, Kyoto, Japan and Advanced Medical Care Center, Kusatsu General Hospital, Kusatsu, Japan, Kusatsu, Japan

  • Department of Endocrinology, Peking Union Medical College Hospital, Beijing, China, Bejing, China

  • Division of Metabolism, Endocrinology, & Diabetes, University of Michigan, Ann Arbor, MI, United States

  • Prince of Songkla University, Hat Yai, Thailand.

  • Pituitary Tumor Center, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea, Seoul, Korea, Democratic People’s Republic of Korea

  • Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea, Seoul, Korea, Democratic People’s Republic of Korea

  • CRCHUM, Montreal, QC, Canada

  • Neuroendocrine & Pituitary Tumor Clinical Center, Massachusetts General Hospital, Boston, MA, USA

Locations

  • Italy

  • United States

  • United Kingdom

  • France

  • Japan

  • China

  • Thailand

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Endocrine/metabolic Diseases (ME)

Disease

  • Cushing's syndrome

Biomarkers

  • N/A

Drug/Treatment

  • LCI699

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Open Label

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved